文献速递血栓与止血

联合免疫抑制治疗获得性血友病A:CyDRi方案高效低毒

Combined immunosuppression for acquired hemophilia A: CyDRi is a highly effective low-toxicity regimen.
PubMed 文献 · Blood · 2022-01-01

本文回顾性分析32例获得性血友病A患者接受统一机构方案CyDRi(环磷酰胺、地塞米松、利妥昔单抗)的数据,31例(96.8%)达到持久完全缓解,29例(90.6%)末次随访存活且均处于完全缓解,毒性可接受且较常用长期激素治疗更轻。

要点

  • CyDRi方案(环磷酰胺+地塞米松+利妥昔单抗)使31/32例(96.8%)获得持久完全缓解。
  • 出血控制中位时间15.5天(范围0-429天,四分位距2.5-29.5天)。
  • 毒性可接受,且较常用长期激素治疗更轻。

核心结论

  • CyDRi方案产生的完全缓解率和总生存率明显高于目前使用的序贯方案。
  • CyDRi被证明是老年获得性血友病A患者免疫抑制治疗的一个有吸引力的选择。

研究设计与样本

  • 回顾性分析32例获得性血友病A患者,接受统一机构方案CyDRi治疗。
  • 所有患者至少接受1个周期CyDRi;必要时重复CyDRi直至缓解,重复不早于前一周期第43天。

主要发现

  • 出血控制中位时间15.5天(范围0-429天,四分位距2.5-29.5天)。
  • 31/32例(96.8%)达到持久完全缓解;29/32例(90.6%)末次随访存活,且均处于完全缓解。
  • 首次完全缓解中位时间77天(范围19-939天,四分位距31-115天)。
  • 毒性和副作用可接受,且较常用长期激素治疗更轻。

关键数值与推荐

  • CyDRi方案:环磷酰胺1000 mg于第1天和第22天;地塞米松40 mg于第1、8、15、22天;利妥昔单抗100 mg于第1、8、15、22天。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Acquired hemophilia A (AHA) is a rare severe autoimmune bleeding disorder with significant morbidity and mortality. Although critical for disease control, there is no consensus for the best immunosuppressive regimen. Most authors use steroids first line, followed by other agents for steroid failures. Upfront combined regimens offer the advantage of reduced steroid exposure and toxicity as well as increased efficacy. We retrospectively analyzed data from 32 patients with AHA treated on an identical such institutional protocol: cyclophosphamide 1000 mg on days 1 and 22, dexamethasone 40 mg on days 1, 8, 15, and 22, and rituximab 100 mg on days 1, 8, 15, and 22 (the regimen was termed CyDRi). All patients received at least 1 cycle of CyDRi. If necessary, CyDRi was repeated until remission, no sooner than day 43 of the previous cycle. Bleeding control was rapidly achieved. The median time for bleeding control was 15.5 days (range, 0-429 days; interquartile range, 2.5-29.5 days). Thirty-one (96.8%) of 32 patients achieved durable complete remission (CR); 29 (90.6%) of 32 patients were alive at last follow-up, all of them in CR. The median time to reach first CR was 77 days (range, 19-939 days; interquartile range, 31-115 days). Toxicity and side effects were acceptable and milder than those of commonly used, prolonged steroid therapies. In conclusion, the CyDRi regimen produced markedly higher CR rates and overall survival than currently used sequential regimens. Taken together, CyDRi proved to be an attractive option for the immunosuppression of elderly patients with AHA.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Simon B, Ceglédi A, Dolgos J, et al. Combined immunosuppression for acquired hemophilia A: CyDRi is a highly effective low-toxicity regimen. Blood. 2022. PMID: 35930747. doi:10.1182/blood.2022016873

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。